KENDALL DYKE: Open Payments
NPI 1558029173 · ABERDEEN, SD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$447 in 14 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $947 · 2025 $447
Food & beverage: $447
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $176 |
| Merck Sharp & Dohme LLC | 2 | $56 |
| Deciphera Pharmaceuticals Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Novartis Pharmaceuticals Corporation | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $27 |
| BeOne Medicines USA, Inc. | 1 | $27 |
| Incyte Corporation | 1 | $23 |
| Janssen Biotech, Inc. | 1 | $22 |
| SpringWorks Therapeutics, Inc. | 1 | $20 |
Products named: IMFINZI, KEYTRUDA, QINLOCK, ICLUSIG, LYNPARZA, KISQALI, INJECTAFER, BRUKINSA.
Industry payments across SD — which companies pay providers there.
